Our study provides evidence about the limitations of macrophage cell therapy in kidney diseases and shows a potential strategy to overcome the inherent M2 plasticity and TGF‐β1 overexpression by Φ‐NGAL transduction. Here, LCN2 is linked to kidney disorder.